DocGo Inc.
- Open
- 0.42
- Day high
- 0.42
- Day low
- 0.40
- Prev close
- 0.41
- Volume
- 639K
- Mkt cap
- $39M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.3
- P/S
- 0.1
- Yield
- —
- Per share
- —
DocGo Inc. (DCGO) is a Healthcare company listed on NASDAQ. The stock is down 74% over the past year. Drillr has 1 published research article covering DCGO.
DocGo Inc. (DCGO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
DCGO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 17, 2026 | $-0.10 | $-0.16 | -64.1% | $73M | -2.6% |
| May 11, 2026 | $-0.02 | $-0.12 | -500.0% | $76M | +4.2% |
| Mar 16, 2026 | $-0.14 | $-1861353.15 | -1310811980.6% | — | — |
| Aug 7, 2025 | $-0.06 | $-0.11 | -83.3% | $80M | +16.7% |
| May 8, 2025 | $-0.01 | $-0.09 | -800.0% | $96M | -3.1% |
| Feb 27, 2025 | $0.05 | $0.04 | -20.0% | $121M | +8.0% |
| Nov 7, 2024 | $0.05 | $0.05 | +0.0% | $139M | +7.2% |
| Feb 28, 2024 | $0.10 | $0.07 | -30.0% | $199M | +2.6% |
| Mar 13, 2023 | $0.05 | $0.11 | +120.0% | $109M | +4.8% |
| Mar 14, 2022 | $0.01 | $0.17 | +1050.2% | $121M | +0.0% |
| Nov 15, 2021 | — | $0.04 | — | $86M | +5.9% |
| Aug 11, 2021 | — | $-0.02 | — | $62M | — |
DCGO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 14, 2026 | Bienstock Leedirector, officer: Chief Executive Officer | Tax | 15,644 | $0.59 |
| Mar 31, 2026 | Bienstock Leedirector, officer: Chief Executive Officer | Tax | 18,811 | $0.57 |
| Dec 16, 2025 | Burdiek Michael Jdirector | Grant | 150,000 | — |
| Dec 16, 2025 | Leite Etalvinadirector | Grant | 150,000 | — |
| Dec 16, 2025 | Bienstock Leedirector, officer: Chief Executive Officer | Grant | 1,113,495 | — |
| Dec 16, 2025 | Smedra Iradirector | Grant | 150,000 | — |
| Dec 16, 2025 | TRAVERS JAMES Mdirector | Grant | 150,000 | — |
| Dec 16, 2025 | ROSENBERG NORMANofficer: CFO and Treasurer | Tax | 65,774 | $0.91 |
| Dec 16, 2025 | ROSENBERG NORMANofficer: CFO and Treasurer | Grant | 429,405 | — |
| Dec 16, 2025 | Bienstock Leedirector, officer: Chief Executive Officer | Tax | 214,131 | $0.91 |
| Dec 16, 2025 | Tendler Ely Ddirector, officer: General Counsel and Secretary | Grant | 100,000 | — |
| Dec 16, 2025 | Tendler Ely Ddirector, officer: General Counsel and Secretary | Sell | 16,850 | $0.91 |
| Dec 16, 2025 | Sugrue Stephenofficer: Chief Compliance Officer | Grant | 321,055 | — |
| Dec 16, 2025 | Sugrue Stephenofficer: Chief Compliance Officer | Tax | 35,968 | $0.91 |
| Sep 11, 2025 | Klasko Stephen K. M.D.director | Grant | 100,000 | — |
Source: DCGO SEC Form 4 filings, latest May 14, 2026. For informational purposes only — not investment advice.
See the full DCGO insider & 13F page →DCGO research & analysis
DocGo Inc. company profile
Overview
DocGo Inc. (NASDAQ:DCGO) is a mobile healthcare and medical transportation services company founded in 2015 and headquartered in New York, New York. The company went public in December 2020 through a SPAC merger. DocGo provides on-demand healthcare services delivered directly to patients' homes, workplaces, and other locations, along with medical transportation services including ambulance and wheelchair transport. The company has evolved from its initial focus on emergency medical services to become a comprehensive mobile healthcare platform serving payers, health systems, and government entities across the United States and United Kingdom.
Business
DocGo operates in the mobile healthcare industry, which represents a growing segment of the broader healthcare delivery market focused on bringing medical services directly to patients rather than requiring them to visit traditional healthcare facilities. The company's core offering is mobile health services delivered through its proprietary technology platform, which coordinates healthcare professionals to provide medical care in patients' homes, offices, and other non-clinical settings. The company operates two primary business segments. The Mobile Health segment generates approximately 47-53% of total revenue and includes services such as care gap closure programs (helping patients complete recommended preventive care), remote patient monitoring for cardiac implantable electronic devices, primary care visits, COVID-19 testing, and specialized screenings like bone density scans and depression assessments. These services are typically contracted with health insurance payers, health systems, and government entities to improve patient outcomes while reducing costs compared to traditional facility-based care. The Medical Transportation Services segment accounts for approximately 47-53% of revenue and provides both emergency response services (ambulances for 911 calls) and non-emergency medical transportation including wheelchair-accessible vehicles and stretcher transport. This segment operates on contracted arrangements with municipalities, health systems, and insurance companies, often using a "leased hour" model where clients pay for dedicated vehicle and crew availability rather than per-transport fees. DocGo also provides event medical services for sporting events, concerts, and other gatherings, though this represents a smaller portion of overall revenue. The company has historically generated significant revenue from government population health programs, including migrant services contracts, though management is strategically shifting away from this volatile revenue source toward more predictable healthcare-focused contracts.
Revenue model
DocGo generates revenue through multiple business models depending on the service line. In the Mobile Health segment, the company primarily operates on fee-for-service contracts with health insurance payers, where DocGo is paid per visit or per patient enrolled in programs like care gap closure. For example, payers contract with DocGo to visit members in their homes to complete annual wellness visits, chronic care management, or preventive screenings that would otherwise require expensive facility visits or remain incomplete. The Medical Transportation segment operates primarily on contracted service agreements using a "leased hour" model, where municipalities and health systems pay DocGo for dedicated ambulance crews and vehicles for specified time periods, regardless of actual transport volume. This provides more predictable revenue compared to per-transport billing. Some transportation contracts also include performance-based components tied to response times and service quality metrics. The company's paying customers include health insurance payers (Medicare Advantage plans, Medicaid managed care organizations, commercial insurers), health systems, municipal governments, and directly-paying consumers. Government contracts, while historically significant, are being de-emphasized due to their volatility and policy-dependent nature. Several factors influence DocGo's margins. Positive margin drivers include the company's ability to achieve economies of scale as it grows, the premium pricing power of mobile services compared to traditional healthcare delivery, and the operational leverage inherent in its technology platform. Negative margin pressures include labor cost inflation in healthcare markets, the need for geographic expansion investments, competitive pressures from traditional healthcare providers entering mobile services, and the regulatory complexity of healthcare reimbursement which can create collection delays or disputes.
Competitive moat
DocGo's competitive moat is moderate but developing, primarily built around operational expertise and network effects rather than strong structural barriers. The company's main competitive advantage lies in its operational complexity and execution capabilities - successfully coordinating mobile healthcare delivery requires sophisticated logistics, regulatory compliance across multiple jurisdictions, integration with various healthcare IT systems, and management of a distributed workforce of healthcare professionals. The company has developed technological integration capabilities with major electronic health record systems like Epic and Athenahealth, creating some switching costs for clients who have integrated DocGo's services into their workflows. Additionally, DocGo's track record and relationships with payers and health systems provide some competitive positioning, as these entities prefer working with proven vendors given the regulatory and quality requirements in healthcare. However, DocGo's moat faces significant competitive threats. Large healthcare incumbents including major health systems, established home healthcare companies, and even technology giants like Amazon (through Amazon Care) have the resources to replicate DocGo's model. Traditional ambulance companies can expand into mobile health services, while telehealth companies can add in-person visit capabilities. The company also faces potential disruption from direct-to-consumer models and changing reimbursement policies that could alter the economics of mobile healthcare delivery. The regulatory environment presents both protection and risk - while healthcare regulations create barriers to entry, they also create compliance costs and reimbursement uncertainties that can quickly impact profitability. DocGo's moat is strongest in markets where it has established payer relationships and operational scale, but remains vulnerable to well-funded competitors and regulatory changes.
Risks & safety
DocGo presents a moderate margin of safety with reasonable financial stability but some operational risks. • Liquidity and Solvency: Strong cash position of $79 million as of Q1 2025, current ratio of 2.44, and positive operating cash flow of $9.7 million in Q1 2025. Debt-to-equity ratio of 0.20 indicates low leverage risk. • Valuation Metrics: Trading at P/E of -7.1 (due to recent losses), P/B of 0.87 (below book value), and EV/EBITDA of -5.9 (negative due to EBITDA losses). Graham Net-Net ratio of 0.83 suggests reasonable asset backing. • Cash Flow Concerns: Company burning cash on EBITDA basis (-$10.6 million in Q1 2025) but generating positive operating cash flow. Management projects return to EBITDA positive in 2026. • Revenue Volatility: Significant revenue decline from $192 million in Q1 2024 to $96 million in Q1 2025, primarily due to loss of government contracts. Guidance revision from $410-450 million to $300-330 million for 2025 indicates execution challenges. • Other Considerations: Stock buyback program demonstrates management confidence, but recent operational struggles and guidance cuts raise questions about near-term execution capability.
Recent development
Over the past few years, DocGo has undergone a significant strategic transformation from a COVID-testing focused company to a comprehensive mobile healthcare platform. The company initially benefited from substantial COVID-19 testing contracts that generated approximately $110 million in revenue in 2021, which declined to $75 million in 2022 as pandemic demand waned. The most significant recent development has been DocGo's aggressive expansion into care gap closure programs with health insurance payers. These programs involve sending healthcare professionals to patients' homes to complete annual wellness visits, chronic care screenings, and preventive care that patients might otherwise skip. The company has grown from zero assigned lives to over 900,000 assigned lives by Q1 2025, with projections to complete over 11,500 care gap closure visits in Q4 2025. DocGo has also been diversifying away from volatile government contracts, particularly those related to migrant services which generated approximately $370 million in revenue in 2024. Management removed the government population health vertical from 2025 guidance due to policy uncertainties and budget cuts, representing a major strategic pivot toward more predictable healthcare-focused revenue streams. The company has made several strategic investments including the acquisition of PTI Health (a mobile phlebotomy company), expansion of remote patient monitoring services to 50,000 cardiac device patients, and development of primary care delivery capabilities. Technology integration has been a key focus, with partnerships established with Epic App Orchard and Athenahealth to seamlessly integrate mobile services into existing healthcare workflows. Recent operational challenges have led to significant guidance revisions, with 2025 revenue expectations cut from $410-450 million to $300-330 million, and EBITDA expectations shifting from positive 5% margins to losses of $20-30 million, though management maintains confidence in returning to profitability by 2026.
DCGO company profile · for informational purposes only — not investment advice.
Track DCGO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free